181 related articles for article (PubMed ID: 33203201)
21. Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
Soni S; Rastogi A; Prasad KT; Behera D; Singh N
Lung Cancer; 2021 Jan; 151():16-19. PubMed ID: 33278669
[TBL] [Abstract][Full Text] [Related]
22. Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring
Simionato F; Calvetti L; Cosci M; Scarparo S; Aprile G
Onco Targets Ther; 2020; 13():12027-12031. PubMed ID: 33262603
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer.
Rybinski B; Hosgood HD; Wiener SL; Weiser DA
Front Oncol; 2020; 10():587377. PubMed ID: 33251146
[TBL] [Abstract][Full Text] [Related]
26. Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the Literature.
Caruso G; Musacchio L; Santangelo G; Palaia I; Tomao F; Di Donato V; Perniola G; Salutari V; Benedetti Panici P
Case Rep Oncol; 2020; 13(3):1317-1324. PubMed ID: 33250748
[TBL] [Abstract][Full Text] [Related]
27. First Experiences with
Prasad V; Zengerling F; Steinacker JP; Bolenz C; Beer M; Wiegel T; Eiber M; Fleshner N; Beer AJ
J Nucl Med; 2021 Jul; 62(7):975-978. PubMed ID: 33246977
[TBL] [Abstract][Full Text] [Related]
28. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
29. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP; Yndestad S; Elzawahry A; Llop-Guevara A; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Vagstad G; Venizelos A; Minsaas L; Leirvaag B; Gudlaugsson EG; Vintermyr OK; Aase HS; Aas T; Balmaña J; Serra V; Janssen EAM; Knappskog S; Lønning PE
Ann Oncol; 2021 Feb; 32(2):240-249. PubMed ID: 33242536
[TBL] [Abstract][Full Text] [Related]
30. A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy.
Cong J; Zhang Y; Xue Y; Zhang C; Xu M; Liu D; Zhang R; Zhu H
Front Microbiol; 2020; 11():583525. PubMed ID: 33240237
[TBL] [Abstract][Full Text] [Related]
31. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by
Piper-Vallillo AJ; Halbert BT; Rangachari D; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2020 Nov; 1(4):100071. PubMed ID: 33225315
[No Abstract] [Full Text] [Related]
32. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.
Kommineni N; Nottingham E; Bagde A; Patel N; Rishi AK; Dev SRS; Singh M
Eur J Pharm Biopharm; 2021 Jan; 158():172-184. PubMed ID: 33220423
[TBL] [Abstract][Full Text] [Related]
33. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
35. Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer.
Giron P; Eggermont C; Noeparast A; Vandenplas H; Teugels E; Forsyth R; De Wever O; Aza-Blanc P; Gutierrez GJ; De Grève J
Int J Cancer; 2021 May; 148(10):2579-2593. PubMed ID: 33210294
[TBL] [Abstract][Full Text] [Related]
36. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.
Wang Y; He Y; Tian P; Wang W; Wang K; Chuai S; Li Y; Zhao S; Wang Y; Li W
Transl Lung Cancer Res; 2020 Oct; 9(5):1952-1962. PubMed ID: 33209615
[TBL] [Abstract][Full Text] [Related]
37. A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients.
Cortellini A; Ficorella C; Crisci R; Divisi D
J Thorac Dis; 2020 Oct; 12(10):6107-6111. PubMed ID: 33209443
[No Abstract] [Full Text] [Related]
38. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
39. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
[No Abstract] [Full Text] [Related]
40. [Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu J; Shi Y; Liu X; Zhang D; Bai Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):460-467. PubMed ID: 35899442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
